Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

10 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Cutaneous End Organ Assessments Week 38 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 38

- 15/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 28 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 28

- 12/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 28.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 32 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 32

- 12/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 24 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 24

- 12/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 20 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 20

- 12/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 20.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 16 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 16

- 12/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 12 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 12

- 10/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 8 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 8

- 9/7/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 8.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 4 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 4

- 11/6/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 4.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Day 1 Pre-Infusion

- 11/6/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma
Itemgroup: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial